Therefore, compounds that inactivate nuclear NR4A1 have been characterized as a new class of chemotherapeutic agents for the treatment of NR4A1 overexpression in pancreatic cancer. The gene discussed is NR4A1; the disease is familial pancreatic carcinoma.